anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE OF REVIEW: This article focuses on pharmacological agents as well as dietary changes aimed at the reduction of the inflammatory burden measured by circulating C-reactive protein concentrations.
RECENT FINDINGS: Over the last years, repurposed as well as new anti-inflammatory agents have been investigated in outcome trials in the cardiovascular field. Currently, a specific inhibition of the inflammatory cascade via the interleukin-6 ligand antibody ziltivekimab is being explored in large-scale outcome trials, after the efficacy of this agent with regard to the reduction of inflammatory biomarkers was proven recently. Next to the investigated pharmacological agents, specific dietary patterns possess the ability to improve the inflammatory burden. This enables patients themselves to unlock a potential health benefit ahead of the initiation of a specific medication targeting the inflammatory pathway.
SUMMARY: Both pharmacological agents as well as diet provide the opportunity to improve the inflammatory profile and thereby lower C-reactive protein concentrations. Whilst advances in the field of specific anti-inflammatory treatments have been made over the last years, their broad implementation is currently limited. Therefore, optimization of diet (and other lifestyle factors) could provide a cost effective and side-effect free intervention to target low-grade vascular inflammation.
PROBLEM TO BE SOLVED: To obtain a hair growing agent having excellent hair-growing activities such as depilation-preventing and hair-generating activities, etc., by including pyrimidine N-oxide derivative. SOLUTION: This hair growing agent includes pyrimidine N-oxide derivative of formulas I and II (R1 is a 1-8C alkyl; R2 is H, a 1-8C alkyl, Br, Cl, nitro or amino; R3 and R4 are each H, a 1-8C alkyl, a 3-8C alkenyl, a heterocycle, etc.), an acylated material thereof, a tautomer thereof or an acid-added salt thereof as an active ingredient. The formulating amounts thereof is 0.001-15wt.%, preferably 0.1-10wt.% based on the hair growing agent. The compound of formula I or II is represented by 2-amino-4-methyl-6-piperidynopyridin-3-oxide. The hair growing agent is preferably applied by transdermal administration such as a direct application or spraying. The daily dose is 0.001-100mg/kg and administered by dividing the dose into one to four portions.
A system and associated methods provide healthcare entities with analyzing capabilities for records of a patient population. The analyzing process seeks to find matches between a piece of clinical knowledge introduced to a healthcare entity and data contained in the patient population records. According to one method, a service generates executable code based on the piece of clinical knowledge. Through a communication with the service, the healthcare entity makes a determination as to what extent the clinical knowledge has relevance to a patient population of the healthcare entity. Based on this determination, the healthcare entity receives at least a portion of the executable code. Then, the records of the patient population may be analyzed by the executable code to register matches of the clinical knowledge with data contained within the records. System activity may then be initiated based on the matches registered.
The WORRK model is a predictive tool (19 items) of the non-return to work risk useful for all kinds of orthopaedic trauma and for patients needing vocational rehabilitation. It is constructed with variables independent of the patient's education and language fluency. It is a short patient's bedside tool and takes less than 20 minutes.
Participants will be supplied with an e-cigarette along with a 4-week supply of e-liquid. Participants will receive training on how to use the device and practice puffing with the e-cigarette during the research visit. They will be instructed to self-regulate administration according to their craving and withdrawal symptoms and to refrain from using other nicotine and tobacco products.
Three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated conformal radiotherapy (IMRT) at a prescribed dose of 54-66 Gy/27-33 f. The combined TKI includes gefitinib, erlotinib, erlotinib, oseltinib, and ametinib. The specific uses are: gefitinib 250 mg orally once daily; erlotinib 125 mg orally three times daily; erlotinib 150 mg orally once daily; oseltinib 80 mg orally once daily; ametinib 110 mg orally once daily. TKI is taken until disease progression or intolerability.
This systematic review and meta-analysis evaluated the efficacy of dexlansoprazole (a proton pump inhibitor-PPI) in resolving heartburn, reflux, and other symptoms and complications resulting from gastroesophageal reflux disease (GERD). The study followed PRISMA 2020 and was registered in PROSPERO (CRD42020206513). The search strategy used MeSH and free terms appropriately adapted for each database. Only randomized clinical trials (RCTs) were included. The Cochrane tool (RoB 2.0) was used to assess the risk of bias, and the certainty of evidence was rated using GRADE. Ten RCTs were included. Dexlansoprazole outperformed the placebo and other PPIs in the resolution of heartburn and reflux symptoms in patients with GERD, with benefits during and after treatment, especially in those with moderate and severe symptoms. The meta-analyses indicated that dexlansoprazole at doses of 30 and 60 mg had more 24 h heartburn-free days and nights compared to the placebo medications; no difference was reported between dexlansoprazole at doses of 30 and 60 mg in heartburn-free nights. A low bias risk and a moderate certainty of evidence were observed. This review confirms the therapeutic effect of dexlansoprazole (placebo-controlled) and its improvements in GERD symptoms compared to another PPI. However, the interpretation of the results should be carried out cautiously due to the small number of included studies and other reported limitations.
The first phase of the data collection process will include one to one interviews with up to twenty (20) frail older people. The pre-selected inclusion criteria for this category of participants include; older people (aged 65 years and over); individuals diagnosed with frailty and receiving (part of their) care services at the Day Hospital; the capacity to give free and fully informed consent; ability to use the English language, as well as judgement by the clinical staff and/or nominated manager that the potential participant can take part in an in-depth interview.
Chronic obstructive pulmonary disease (COPD) is an irreversible and progressive chronic inflammatory lung disease which affects millions of people worldwide. Activated fibroblasts are observed to accumulate in lung of COPD patients and promote COPD progression through aberrant extracellular matrix (ECM) deposition. In this study, we identified that miR-1307-5p expression was significantly increased in lung fibroblasts derived from COPD patients. Mechanistically, we found that upregulation of miR-1307-5p promoted TGF-β induced lung fibroblast activation and transdifferentiation. We also identified FBXL16 as a direct target for miR-1307-5p mediated myofibroblast activation in COPD. Knockdown of FBXL16 by siRNA prominently increased the expression of myofibroblast markers in MRC-5 fibroblasts after TGF-β administration. Ectopic expression of FBXL16 in MRC-5 counteracted miR-1307-5p agomir-induced fibroblast transdifferentiation. Furthermore, We found that miR-1307-5p promoted pulmonary fibroblast transdifferentiation through FBXL16 regulated HIF1α degradation. In general, our findings indicate that miR-1307-5p is important for COPD pathogenesis, and may serve as a potential target for COPD treatment.
<P>PROBLEM TO BE SOLVED: To provide an oxidation hair dye which can exhibit a sufficient hair-dyeing force and simultaneously improve the fastness of hair.  <P>SOLUTION: This oxidation hair dye comprises a main hair dye and an auxiliary hair dye. The main hair dye comprises the first agent comprising an oxidation dye and an alkali agent, and the second agent comprises an oxidizing agent. The first agent and the second agent are mixed with each other just before the oxidation hair dye is used. Namely, the main hair dye is used in a state that the oxidation dye, the alkali agent and the oxidizing agent are mixed. The auxiliary hair dye preferably contains a chelating agent in an amount of ≥3 mass%. The auxiliary hair dye is brought into contact with the main hair dye just before the oxidation hair dye is used.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Inflammation and aging slow down the recovery rate of the elderly, making it extremely difficult for them to restore their bodies to a youthful state. Age-related deterioration of bodily tissues and organ functions often manifest as inflammation and tumors, which are key factors in inhibiting aging. Researchers have found that the body's nervous system is closely related to initiating the body's regenerative repair functions. The formulation solution is actively absorbed by the human nervous system, achieving drugs delivery over long distances along the nervous system. The recovery speed of the elderly can be accelerated by using formula disclosed in this application. This application combines anti-aging and regeneration, emphasizing the increase in concentration of sodium ions and neurotransmitter-like small molecules in the nervous system as key factors for repair and regeneration. This application belongs to the field of biomedicine.
A D2 receptor agonizing agent with a 5HT1A receptor agonizing agent or a a2 adrenergic receptor agonizing agent is used to treat Parkinson's disease, ADHD or microadenoma. A a2 adrenergic receptor agonizing agent with a 5HT1A receptor agonizing agent is used to treat Parkinson's disease, ADHD or microadenoma. The D2 receptor agonizing agent can be a compound of formula (I), pergolide, bromocriptane, ropinerol or pramipexole. The 5HT1A receptor agonizing agent can be a compound of formula (I), buspirone, gepirone, ipsapirone or flexinoxan. The a2 adrenergic receptor agonizing agent can be a compound of formula (I), yohimbine or idazoxan. In formula (I) X is N or CH; Y is a group of formula (II) and Z is a group of formula (III).
The present invention relates to nucleic acid sequences encoding a 22.5 kD Streptococcus uberis protein and to parts of such nucleic acid sequences that encode an immunogenic fragment of such proteins, and to DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof. The invention also relates to a 22.5 kD Streptococcus uberis protein and immunogenic parts thereof encoded by such sequences. Furthermore, the present invention relates to vaccines comprising such nucleic acid sequences and parts thereof, DNA fragments, recombinant DNA molecules, live recombinant carriers and host cells comprising such nucleic acid sequences or such parts thereof, proteins or immunogenic parts thereof and antibodies against such proteins or immunogenic parts thereof. Also, the invention relates to the use of said proteins in vaccines and for the manufacture of vaccines. Moreover, the invention relates to the use of said nucleic acid sequences, proteins or antibodies for diagnostic or vaccination purposes. Finally the invention relates to diagnostic kits comprising such a nucleic acid, protein or antibodies against such protein.
Telcagepant 280 mg, oral, tablet, across 4 migraine attacks. For migraine attack 1 only, if no headache relief is obtained after 2 hours post dose, or if the migraine recurs after 2 hours of the initial treatment, participants may receive an optional second dose of telcagepant 280 mg or placebo.
The population of the study consists of children aged 12-17 who were treated in the pediatric emergency departments of the designated hospitals between December 2021 and July 2022 and met the working criteria. The sample consists of 300 children who applied to the pediatric emergency service between December 2021 and July 2022 and met the research criteria. Socio-Demographic presentation form and Visual Analog Scale were used as data collection tools. Statistical analysis of the data was made in SPSS 22 package program.
This single-center, prospective study will be conducted at one site in the United Kingdom. Up to 30 subjects will be enrolled and treated with Gel-Bead. Prospectively. Enrolled Gel-Bead subjects will be followed at 1-month and 3-months post-procedure.

Data from subjects treated with Gel-Bead will be compared to data from a previously unpublished, but widely presented, 100-patient cohort study at the University Hospital Southampton. This study evaluated 20 subjects in five different treatment groups for the treatment of symptomatic uterine fibroids. The five treatment groups include gelatin foam slurry, Embospheres, polyvinyl alcohol (PVA), Bead Block and Embozenes.
OBJECTIVE: In this prospective non-randomized study we reported our experience related to planum sphenoidale (PS) and tuberculum sellae (TS) meningiomas in a similar cohort of patients operated via the endonasal or the supraorbital route. A comprehensive quality of life analysis has been performed.
METHODS: Being comparable in general features, between November 2017 to January 2020, a total of 20 patients with anterior skull base meningioma were included. Hence, 10 patients were treated using the supraorbital keyhole procedure (SO) while 10 patients received an endoscopic endonasal approach (EEA). Both surgical techniques were analyzed and compared. Quality of life has been analyzed with the SF-36 questionnaire.
RESULTS: Twenty patients were identified who underwent either EEA (n=10) or SO (n=10). The average extent of resection achieved was not significantly different between the 2 groups. Post-operatively, the EEA group demonstrated a longer hospital stay and bed days compared with SO patients as well as a longer surgical time. There was a significant rate of more CSF leakage after EEA then after SO (20% vs 0%, p=0,0491). The follow-up period resulted shorter in the SO group, with a slight increased recurrence rate. Overall, no differences in visual outcome were detected. There were no differences in terms of quality of life between the two groups in all the explored items.
CONCLUSIONS: In this single-center single-surgeon study of similarly sized and located PS and TS meningiomas, EEA showed longer hospital stays with higher degree of CSF leak compared with the SO group. Supraorbital craniotomy via eyebrow incision reported a comparable quality of life results, even if with a slightly higher percentage of recurrence and less follow-up.
BACKGROUND: The Enoyl-CoA hydratase/isomerase family plays a crucial role in the metabolism of tumors, being crucial for maintaining the energy balance and biosynthetic needs of cancer cells. However, the enzymes within this family that are pivotal in gastric cancer (GC) remain unclear.
METHODS: We employed bioinformatics techniques to identify key Enoyl-CoA hydratase/isomerase in GC. The expression of ECHDC2 and its clinical significance were validated through tissue microarray analysis. The role of ECHDC2 in GC was further assessed using colony formation assays, CCK8 assay, EDU assay, Glucose and lactic acid assay, and subcutaneous tumor experiments in nude mice. The mechanism of action of ECHDC2 was validated through Western blotting, Co-immunoprecipitation, and immunofluorescence experiments.
RESULTS: Our analysis of multiple datasets indicates that low expression of ECHDC2 in GC is significantly associated with poor prognosis. Overexpression of ECHDC2 notably inhibits aerobic glycolysis and proliferation of GC cells both in vivo and in vitro. Further experiments revealed that overexpression of ECHDC2 suppresses the P38 MAPK pathway by inhibiting the protein level of MCCC2, thereby restraining glycolysis and proliferation in GC cells. Ultimately, it was discovered that ECHDC2 promotes the ubiquitination and subsequent degradation of MCCC2 protein by binding with NEDD4.
CONCLUSIONS: These findings underscore the pivotal role of the ECHDC2 in regulating aerobic glycolysis and proliferation in GC cells, suggesting ECHDC2 as a potential therapeutic target in GC.
This is a prospective, multicenter, single-arm, phase II trial. A total of 58 patients will be enrolled. Eligible patients will be registered and receive three cycles of CAPOX plus sintilimab and bevacizumab biosimilar (IBI305) regimen. Radical D2 gastric cancer resection will be performed 6-8 weeks after the last administration of chemotherapy plus plus sintilimab and bevacizumab biosimilar (IBI305). The primary endpoint of the study is the pathological complete response (pCR) rate. Secondary endpoints include R0 resection rate, major pathological response (MPR), event-free survival (EFS), overall survival (OS) and safety profile of the neoadjuvant regimen.
This self-help training is exclusively provided via Internet over a period of 10 weeks. The treatment is based on the cognitive-behavioral approach and consists of 18 modules with helpful strategies to cope with tinnitus (e.g., applied relaxation, positive imagery, attention shift exercises, cognitive restructuring, sleep management, concentration management,). All modules include an information text, detailed practice instructions, worksheets and homework assignments. At the end of each treatment week, there is an e-mail contact between the participants and their therapist. The participants report on their work with the modules and if they had encountered any problems. The therapist provides feedback, support and recommendations on how to proceed.
An herbal extract which is effective in treating the symptoms of menopause is disclosed. The herbal extract comprises an aqueous suspension of a plurality of fermentation products of the herb  Angelica sinensis . The suspension is made by suspending a quantity of crushed  Angelica sinensis  with a quantity of active yeast in a volume of water and then permitting the yeast to ferment the crushed  Angelica sinensis . The fermentation is preferably carried out at a temperature selected for optimum fermentation period of at least seven days. The optimum fermentation temperature is preferably between 10° C. to 20° C. The fermented mixture may then be filtered after the end of the fermentation period to remove a majority of any coarse solids remaining in the suspension. A yeast nutrient mixture may also be added to the suspension prior to fermentation. Preferably, the fermentation period is less than 30 days.
Patients with smoldering multiple myeloma receive lenalidomide PO QD alone on days 1-14 OR in combination with dexamethasone PO QD on days 1, 8 and 15. Treatment for cycle 1 continues for 21 days in the absence of disease progression or unacceptable toxicity. Patients then receive lenalidomide PO QD on days 1-21 alone or in combination with dexamethasone PO QD on days 1, 8, 15, and 22, or in combination with another drug. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
From baseline to 16-months, participants randomized to the intervention arm will have access to the LuvHub web app intervention and all of its contents (5 modules, resources, etc.), including post-baseline assessments that will occur every 4 months (4, 8, 12, \& 16-months).
The intervention will be applied to the reiki group to be applied in the application laboratory of the midwifery department of the faculty of health sciences. Reiki therapy will be applied by a practitioner with a Reiki application certificate in the application laboratory for 30 minutes while the participants lie down with their eyes closed. 4 sessions of reiki application will be applied to the intervention group for a month. Reiki application will start from the time of menstruation, the first pain scores and comfort conditions will be recorded. Menstruation and general comfort after 4 sessions will be recorded. Any medication and side effects during menstruation with the last reiki application will be recorded by the research team member.
A wireless locating system and method include receiving first messages at a server. The first messages include bed location data entered manually on a user interface of a first patient bed. The first messages also include signal strength data from a plurality of wireless access points in communication with the first patient bed. A first signal strength profile for the first patient bed at a first location is built by the server. The first patient bed is removed from the first location and a second bed is moved into the first location. The second patient bed does not have manual location data entry capability. A second signal strength profile is built by the server for the second patient bed. The server compares the second signal strength profile with the first signal strength profile and determines that the second patient bed is at the first location if the second signal strength profile matches the first signal strength profile.
Investigators used Oculus Quest All-in-one Virtual Reality Gaming Headset (128 GB) VR system. Before the intervention, the investigators introduced the equipment and instructed study participants on how to wear and activate the headsets. The laboring women who enrolled in the virtual reality group first wore the headsets in early labor (Cervical dilation 3 cm) for 20 minutes. The patients were offered to choose among several virtual environments including orange sunset, green meadows, black beginning, red savannah, blue deep, blue moon, blue ocean, white winter, and red fall. Cards printed out from the images of the Nature Trek application representing these novel immersion options were provided to the patients to help them pick up their preferred environment in advance. The second implementation of virtual reality headsets was after the epidural analgesia in the active phase of labor for another 20 minutes (Cervical dilation 6-7cm).
The invention provides an application of sanbaicaoketone in preparing a medicament for treating psoriasis. Belongs to the technical field of medicines. The saururus chinensis ketone can effectively protect the psoriasis-like skin injury of mice induced by imiquimod, improve skin scales, erythema, thickening and abnormal differentiation of epidermis, has a certain inhibition effect on local and systemic skin inflammation, and inhibits infiltration of spleen and lymph node innate immune cells of peripheral immune organs. At the in vitro cellular level, saururus chinensis ketone can inhibit transcription of keratinocyte inflammatory mediators, chemokines, differentiation and other genes, and regulate M1/M2 polarization of macrophages. The saururus chinensis ketone can be used for treating psoriasis, and can expand the potential application value of saururus chinensis ketone in other various skin inflammatory diseases. In addition, the invention also provides a pharmaceutical composition for psoriasis, which contains saururus chinensis ketone or pharmaceutically acceptable salt thereof, and can be prepared into various dosage forms to cope with psoriasis with different types and different disease courses.